226 related articles for article (PubMed ID: 19549121)
1. Improved detection and reduced early recurrence of non-muscle-invasive bladder cancer using hexaminolaevulinate fluorescence cystoscopy: results of a multicentre prospective randomized study (PC B305).
Mostafid H; Bunce C;
BJU Int; 2009 Oct; 104(7):889-90. PubMed ID: 19549121
[No Abstract] [Full Text] [Related]
2. Blue-sky thinking about blue-light cystoscopy.
Thomas K; O'Brien T
BJU Int; 2009 Oct; 104(7):887-9. PubMed ID: 19583718
[No Abstract] [Full Text] [Related]
3. [Fluorescence diagnosis and photodynamic therapy in urology].
Stepp H; Waidelich R
Aktuelle Urol; 2007 Nov; 38(6):455-64. PubMed ID: 17987533
[TBL] [Abstract][Full Text] [Related]
4. The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer.
Bunce C; Ayres BE; Griffiths TR; Mostafid H; Kelly J; Persad R; Kockelbergh R
BJU Int; 2010 Feb; 105 Suppl 2():2-7. PubMed ID: 20089091
[No Abstract] [Full Text] [Related]
5. Blue light cystoscopy for detection and treatment of non-muscle invasive bladder cancer.
Mark JR; Gelpi-Hammerschmidt F; Trabulsi EJ; Gomella LG
Can J Urol; 2012 Apr; 19(2):6227-31. PubMed ID: 22512972
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of macroscopic 5-aminolevulinic acid (ALA)-inducer fluorescence in transurethral resection of non-invasive bladder cancer].
Danil'chenko DI; Koenig F; Riedl K; Schnorr D; Waldman A; Al-Shukri S; Loening SA
Vopr Onkol; 2003; 49(6):734-7. PubMed ID: 14976918
[TBL] [Abstract][Full Text] [Related]
7. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.
Daniltchenko DI; Riedl CR; Sachs MD; Koenig F; Daha KL; Pflueger H; Loening SA; Schnorr D
J Urol; 2005 Dec; 174(6):2129-33, discussion 2133. PubMed ID: 16280742
[TBL] [Abstract][Full Text] [Related]
8. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy.
Schmidbauer J; Witjes F; Schmeller N; Donat R; Susani M; Marberger M;
J Urol; 2004 Jan; 171(1):135-8. PubMed ID: 14665861
[TBL] [Abstract][Full Text] [Related]
9. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer.
Babjuk M; Soukup V; Petrík R; Jirsa M; Dvorácek J
BJU Int; 2005 Oct; 96(6):798-802. PubMed ID: 16153204
[TBL] [Abstract][Full Text] [Related]
10. Recent developments in fluorescence cystoscopy: do novel agents bring a benefit?
Schmidbauer J; Marberger M
Curr Opin Urol; 2007 Sep; 17(5):347-51. PubMed ID: 17762629
[TBL] [Abstract][Full Text] [Related]
11. Editorial comment.
Scarpa RM; Cracco CM
Urology; 2009 Dec; 74(6):1286-7; author reply 1287-8. PubMed ID: 19962530
[No Abstract] [Full Text] [Related]
12. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.
Denzinger S; Burger M; Walter B; Knuechel R; Roessler W; Wieland WF; Filbeck T
Urology; 2007 Apr; 69(4):675-9. PubMed ID: 17445650
[TBL] [Abstract][Full Text] [Related]
13. Hexylaminolaevulinate 'blue light' fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology.
Ray ER; Chatterton K; Khan MS; Thomas K; Chandra A; O'Brien TS
BJU Int; 2009 May; 103(10):1363-7. PubMed ID: 19076151
[TBL] [Abstract][Full Text] [Related]
14. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
15. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy : A multicenter randomized, double-blind, placebo-controlled trial.
Stenzl A; Penkoff H; Dajc-Sommerer E; Zumbraegel A; Hoeltl L; Scholz M; Riedl C; Bugelnig J; Hobisch A; Burger M; Mikuz G; Pichlmeier U
Cancer; 2011 Mar; 117(5):938-47. PubMed ID: 21351082
[TBL] [Abstract][Full Text] [Related]
16. Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance.
Malmström PU; Grabe M; Haug ES; Hellström P; Hermann GG; Mogensen K; Raitanen M; Wahlqvist R
Scand J Urol Nephrol; 2012 Apr; 46(2):108-16. PubMed ID: 22087730
[TBL] [Abstract][Full Text] [Related]
17. [Fluorescence diagnosis in patients with non-muscle invasive bladder cancer: results of a metaanalysis].
Kausch I; Sommerauer M; Montorsi F; Stenzl A; Jacqmin D; Jichlinski P; Jocham D; Ziegler A; Vonthein R
Aktuelle Urol; 2010 May; 41(3):171-7. PubMed ID: 20486035
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy.
Zaak D; Karl A; Knüchel R; Stepp H; Hartmann A; Reich O; Bachmann A; Siebels M; Popken G; Stief C
BJU Int; 2005 Aug; 96(2):217-22. PubMed ID: 16001963
[TBL] [Abstract][Full Text] [Related]
19. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin.
Ray ER; Chatterton K; Khan MS; Chandra A; Thomas K; Dasgupta P; O'Brien TS
BJU Int; 2010 Mar; 105(6):789-94. PubMed ID: 19832725
[TBL] [Abstract][Full Text] [Related]
20. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.
Fradet Y; Grossman HB; Gomella L; Lerner S; Cookson M; Albala D; Droller MJ;
J Urol; 2007 Jul; 178(1):68-73; discussion 73. PubMed ID: 17499291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
